Cancer Vaccine by Fusions of Dendritic and Cancer Cells

Table 1

Asessment of the fusions vaccine.

	Fusions
Tumor	Dendritic cell	Tumor	Adjuvant	Patients (n)	Clinical response	Ref.
Melanoma	Allogeneic	Autologous		16	1 (CR)	[113, 114]
					1 (PR)
					5 (SD)
					9 (PD)
Glioma	Autologous	Autologous		8	2 (PR)	[115]
					1 (SD)
					5 (PD)
Melanoma	Autologous	Autologous		17	1 (PR)	[116]
					1 (SD)
					15 (PD)
Melanoma	Allogeneic	Autologous	rh IL-2	11	1 (SD)	[117]
					10 (PD)
Glioma	Autologous	Autologous	rh IL-12	12	3 (PR)	[115, 118]
					2 (MR)
					4 (SD)
					3 (PD)
Breast cancer	Autologous	Autologous	rh IL-12	2	1 (SD)	[115, 118]
					1 (PD)
Gastric/Colorectal carcinoma	Autologous	Autologous	rh IL-12	3	1 (SD)	[115, 118]
					2 (PD)
Ovarian carcinoma	Autologous	Autologous	rh IL-12	3	2 (SD)	[115, 118]
					1 (PD)
Melanoma	Autologous	Autologous	rh IL-12	4	4 (PD)	[115, 118]
Breast cancer	Autologous	Autologous		10	2 (PR)	[17]
					1 (SD)
					7 (PD)
Renal cell carcinoma	Autologous	Autologous		13	5 (SD)	[17]
					8 (PD)
Renal cell carcinoma	Allogeneic	Autologous		20	2 (PR)	[106]
					8 (SD)
					10 (PD)
Hepatocellular carcinoma	Autologous	Autologous		1	1 (PD)	[10]
Renal cell carcinoma	Allogeneic	Autologous		10	1 (PR)	[107]
					6 (SD)
					3 (PD)

CR: complete response; PR: partial response; MR: mixed response; SD: stable disease; PD: progressive disease.